# In-Vivo Activated T-Cell Depletion to Prevent GVHD

> **NCT00594308** · NA · TERMINATED · sponsor: **Indiana University** · enrollment: 10 (actual)

## Conditions studied

- Acute Myelogenous Leukemia
- Acute Lymphocytic Leukemia
- Chronic Myelogenous Leukemia
- Chronic Lymphocytic Leukemia
- Myelodysplasia
- Lymphoma, Non-Hodgkin's
- Mantle-Cell Lymphoma
- Hodgkin's Disease
- Multiple Myeloma
- Myelofibrosis

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **DRUG:** Cyclosporine
- **DRUG:** Mycophenolate mofetil
- **DRUG:** Basiliximab

## Key facts

- **NCT ID:** NCT00594308
- **Lead sponsor:** Indiana University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-10
- **Primary completion:** 2008-10
- **Final completion:** —
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Treatment ineffective
- **Last updated:** 2014-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00594308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00594308, "In-Vivo Activated T-Cell Depletion to Prevent GVHD". Retrieved via AI Analytics 2026-08-19 from https://api.ai-analytics.org/clinical/NCT00594308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*